The Latest Breaking News from FDA

The recalled coffee pods were sold in 10-count boxes

U.S. health officials are cracking down on an opioid-like ingredient being added to drinks, supplements and other products

Stock of Sarepta Therapeutics Inc. (NASDAQ:SRPT) surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration’s (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta’s gene therapy for Duchenne Muscular Dystrophy.

You’ve probably seen claims that chemical sunscreens are harmful—but what’s the real story behind those warnings? With buzz on social media and litigation around ingredients like oxybenzone, many wonder if they should switch. The latest science offers clarity: chemical filters are absorbed into the bloodstream—but current evidence doesn’t show this…

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares were halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an 8-year-old boy who had received Elevidys, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) gene therapy for Duchenne muscular dystrophy.

Novo CEO ousted in May, in place until successor named

The debate over cane sugar vs. corn syrup is heating up, raising questions about cost, policy, and, in some cases, soda taxes.